Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $41,577.60 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 2,130 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $19.52, for a total transaction of $41,577.60. Following the sale, the insider now directly owns 78,335 shares in the company, valued at approximately $1,529,099.20. The trade was a 2.65 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Castle Biosciences Trading Down 4.4 %

Shares of CSTL opened at $18.76 on Friday. Castle Biosciences, Inc. has a twelve month low of $16.97 and a twelve month high of $35.84. The company has a market cap of $525.41 million, a P/E ratio of 93.80 and a beta of 0.98. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. The company’s fifty day simple moving average is $25.99 and its 200-day simple moving average is $28.70.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on CSTL shares. Stephens reaffirmed an “overweight” rating and set a $41.00 price target on shares of Castle Biosciences in a research note on Thursday, January 2nd. Robert W. Baird upped their price target on shares of Castle Biosciences from $36.00 to $37.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $40.00.

Institutional Investors Weigh In On Castle Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in CSTL. US Bancorp DE raised its stake in shares of Castle Biosciences by 1,889.2% in the third quarter. US Bancorp DE now owns 4,615 shares of the company’s stock valued at $132,000 after acquiring an additional 4,383 shares during the period. Principal Financial Group Inc. grew its holdings in shares of Castle Biosciences by 2.7% in the third quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock worth $43,879,000 after purchasing an additional 40,377 shares during the last quarter. Assetmark Inc. grew its holdings in shares of Castle Biosciences by 16.8% in the third quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock worth $149,000 after purchasing an additional 748 shares during the last quarter. Lisanti Capital Growth LLC grew its holdings in shares of Castle Biosciences by 60.2% in the third quarter. Lisanti Capital Growth LLC now owns 154,710 shares of the company’s stock worth $4,412,000 after purchasing an additional 58,160 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of Castle Biosciences in the third quarter worth about $1,478,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.